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ABSTRACT OF THE THESIS 
THE DEVELOPMENT OF A NOVEL POLYMER BASED SYSTEM FOR GENE 
DELIVERY 
by 
Anh Van Le 
Florida International University, 2015 
Miami, Florida 
Professor Wei-Chiang Lin, Major Professor 
Gene therapy involves the use of nucleic acids, either DNA or RNA for the 
treatment, cure, or prevention of human diseases. Synthetic cationic polymers are 
promising as a tool for gene delivery because of their high level of design flexibility for 
biomaterial construction and are capable of binding and condensing DNA through 
electrostatic interactions.  
Our lab has developed a novel polymer (poly (polyethylene glycol-dodecanoate) 
(PEGD), a polyester of polyethylene glycol (PEG) and dodecanedioic acid (DDA). PEGD 
is a linear viscous polymer that self-assembles into a vesicle upon immersion in an 
aqueous solution. A copolymer of dodecanedioc acid and polyethylene glycol (PEG) was 
synthesized at a 1:1 ratio. Furmaric (FA) or itaconic acid (IA) was used to suppress DDA 
in the PEGD copolymer at an 80:20 ratio (DDA: furmaric/itaconic acid) to form the 
PEGDF/I variant.  PEGDF/I are then modified through the Michael addition of Protamine 
Sulfate (PEGDF/I-PS) and Cys-Arg8 (PEGDF/I-CA) peptide to the carbon-carbon double 
bond on the polymer backbone to introduce a positive charge.  
The modified PEGDF/I polymers were capable of binding and condensing DNA. 
Transfection of HEK 293 cells with pTurboGFP plasmid using modified PEGDF/I 
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polymers was successful but showed varied efficiency. The PEGDF/I-CA polymer had 
around 30% transfection efficiency and was shown to be non-cytotoxic. 
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CHAPTER 1 LITERATURE REVIEW 
1.1. Gene therapy 
The concept of using genes as a drug for human disease therapy was originally 
conceived around the early 1970’s as a result of our increased understandings of human 
gene function, how their mutations impacted cellular behavior, and the development of 
more effective methods for the delivery of DNA into mammalian cells (6). Gene therapy 
involves the use of nucleic acids, either DNA or RNA, for the treatment, cure, or 
prevention of human diseases (1-3). The underlying idea of gene therapy involves the 
transfer of genetic material into specific cells responsible for diseases. Depending upon 
the type of disease, gene therapy can be employed to either replace missing or defective 
endogenous genes with a functional copy or by reducing (or silencing) the production of 
harmful or defective gene products (2, 4). Although the concept of gene therapy is 
promising for treating diseases, the transfer of genetic material into higher organisms still 
remains an enormous technical challenge. The hydrophobic and apolar membranes of 
mammalian cells presents a formidable barrier for the movement of large polyanion such 
as DNA and RNA from the extracellular space into the cytosol (6). Thus, the fundamental 
challenge for successful gene therapy is finding both a safe and effective delivery system 
to facilitate the transfer of nucleic materials. Currently, the delivery of genetic material 
can be divided into two categories: viral and non-viral methods (1-4).  
1.2. Viral vectors for the delivery of genetic material 
 Viral delivery of genetic material, also known as transduction, is a delivery 
method in which we exploit the ability of viruses to transfer DNA into target cells. 
Viruses have evolved over millions of years an efficient mechanism to internalize their 
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own genome into targeted cells. A viral particle can be viewed simply as a nano-sized 
object composed of nucleic acid and a few proteins that can prevent its degradation in the 
extracellular environment, and also facilitate its internalization into cells. The basic 
approach of viral gene delivery involves the packaging of DNA into a virus particle and 
the transfer of gene by the normal viral infection route. Since viruses are naturally 
pathogenic, steps must be taken to eliminate certain aspect of the viral genome 
responsible for disease (such as its capability to replicate). An ideal viral vector would 
take into account the following: 1) efficient and easy production, 2) alleviate safety 
concerns, 3) sustained and regulated transgene expression, 4) capable of targeting 
specific cell types, 5) capable of infecting both mitotic and post-mitotic cells, and 6) able 
to integrate at specific sites within the targeted cell genome to enable repairs of the 
defective gene (3-4).    
 The general principle common to all viral vector systems consist of (1) the 
removal of most genes coding for viral proteins, especially those that are pathogenic, (2) 
maintenance of the cis-acting sequences of the viral genome required for viral replication, 
and (3) expressing the viral replication proteins in packaging cells (6). The gene of 
interest is integrated into a viral vector cassette and is delivered into packaging cells 
where the viral replication proteins are expressed. This produces viral particles with the 
transgene incorporated within the viral genome.  
 Viral vectors can be divided into two type of vectors: integrating and non-
integrating. Integrating viral vectors contain a reverse transcriptase function that allows 
them to incorporate their genome into targeted cells. Retroviral and adeno-associated 
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virus vectors have integrating functions. Non-integrating viral vectors are not capable of 
integrating their genome into the targeted cells. Adenovirus viral vectors are non-
integrating. 
 One significant advantage of viral DNA vectors is their extremely high 
transfection efficiency in a variety of human tissues. Gene expression using viral vectors 
has been achieved with high transfection efficiencies in tissues such as kidney, heart, 
muscle, eye and ovary (14). Retroviral vectors are capable of transfecting high 
populations (45%-95%) of primary human endothelial and smooth muscle cells, (a class 
of cells that are generally extremely difficult to transfect) (14). Despite such impressive 
statistics for viral gene transfer, there are several concerns over the use of viruses to 
deliver DNA therapeutics in humans. One of the chief concern is the toxicity of viruses 
and the potential of generating a strong immune response because of their proteinaceous 
capsid. In 1999 as a result of the death of patient suffering a lethal immune response to 
the adenovirus vector used for gene therapeutics, all clinical trials were suspended (14). 
 Another disadvantage of viral gene vectors is the randomness by integrating 
vectors. Since there is no control over the exact location of insertion, random gene 
transfer can generate insertional mutagenesis that may inhibit expression of normal 
cellular genes or activate oncogenes. Another disadvantage is the limiting size of the 
expression plasmid that can be incorporate into the viral cassette. The targeted cells can 
also develop immunity to viral infection and are resistant to repeated infection. The 
production of viral titers is also very expensive and there are few issues that exist for 
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scale up production. These issues must be address in order to further advance the use of 
viral vectors for gene therapeutics. 
1.3. Non-viral systems for the delivery of genetic material 
 Non-viral systems can circumvent some of the problems associated with viral 
vectors.  Non-viral delivery of DNA/RNA-based therapeutics can be broken down into 
two categories: delivery of genetic material is facilitated by either (1) physical forces or 
(2) a synthetic or natural compound.  
Non-viral delivery via a synthetic or natural compound relies upon cationic 
polymers or lipids to form condensed complexes with negatively charged DNA/RNA 
through electrostatic interactions. The cationic complexes protect the genetic materials 
and facilitate cellular uptake. The advantages that are provided with a cationic polymer or 
lipid delivery system includes their ability to be produced at a large scale, their low 
immunogenic response, the possibility of selected modifications to their structural 
makeup and the capacity to carry large inserts (8-11). Currently, the transfection 
efficiency of these cationic vectors is still lower than that of their viral counterparts but 
the ability to modify the cationic vectors (such as the addition of binding ligands) can 
steadily improve transfection efficiency. The ideal objective in gene therapy via a 
systemic approach requires the development of a stable and non-toxic gene vector that 
can encapsulate genetic material and is also capable of delivering them into specific cell 
types for therapeutic purposes.   
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1.3.1. Physical forces as a gene delivery method 
Physical forces can be used to create a change in the physiology of the cellular 
membrane (such as creating holes or defects) to allow for the passage of genetic material. 
The physical forces that are used to create a transient membrane are local or rapid 
systemic injection, particle impact, electric pulse, ultrasound, or laser irradiation (7). 
Techniques such as electroporation, sonoporation, gene gun delivery, needle and jet 
injection relies upon physical forces to alter the plasma membrane to allow for the uptake 
of genetic materials. In cancer gene therapeutics, direct injection of free DNA to tumor 
sites has been shown to produce high levels of gene expression (11). Direct injection is 
limited to tissues that are easily accessible such as skin and muscle tissues. Systemic 
delivery via direct injection is unsuitable due to the presence of nucleases in the body’s 
serum (11). Since the scope of this thesis is to develop a novel cationic polymer system, 
the review of physical techniques will stop here.  
1.3.2. Cationic lipids for gene delivery 
 Cationic lipids (also called cytofectin or lipofection reagents) are one group of 
synthetic vectors that are commonly used in gene delivery. They were first used for gene 
therapy in 1987 by Felgner et al (11). Since then, numerous cationic lipids have been 
synthesized and developed for use in gene delivery in cell culture and animals. There are 
many advantages that are offered by cationic lipids, such as: they are technically simple 
in design, are easy to formulate, are commercially available, and may be tailored for 
specific applications. 
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 Cationic lipids are made up of a cationic head group that is attached to a lipid 
hydrophobic tail group by a linker. The positively charged head group is necessary for 
the binding of the negatively charged phosphate groups on nucleic acid. Therefore all 
cationic lipids are positively charged amphiphile systems. Cationic lipids and DNA 
complexes are called lipoplex. Cationic lipids can be classify into three different 
subgroups based upon their different structural characteristics: (1) monovalent aliphatic 
lipids that are characterized by a single amine in their head moiety, (2) multivalent 
aliphatic lipids with multiple amine functional groups in their polar head unit, (3) lipids 
that are cationic cholesterol derivatives (20).  
 When DNA is mixed with cationic liposomes two possible phase structures are 
formed, lamellar or inverted hexagonal. The lamellar form is a condensed and globular 
structure with DNA monolayers sandwiched between cationic lipid bilayers (11). The 
inverted hexagonal phase structure consists of DNA coated with cationic lipid 
monolayers arranged on a two-dimensional hexagonal lattice. For transfection application 
the cationic lipids are generally mixed with helper lipids, such as DOPE (1,2-dioleyl-sn-
glycerol-3-phosphoethanolamine) to promote the conversion from the lamellar phase 
structure to an inverted hexagonal phase structure which increases transfection efficiency 
(11). 
 Lipoplexes have recently been used for the siRNA delivery in in vivo studies. In a 
recent study, by Liu et al (21), using Lipofectamine 2000 (a commercially available 
cationic lipid reagent) they were able to deliver hdm2-siRNA to MCF-7 human breast 
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cancer cells that were implanted in rats. By silencing hdm2 in the MCF-7 cancer cells, 
cell apotheosis was increased and caused a decreased in proliferation.   
1.4. Cationic polymer as a gene delivery system 
 Synthetic cationic polymers are promising as a tool for gene delivery because of 
their high level of design flexibility for biomaterial construction. Cationic polymers are 
capable of binding and condensing DNA into nano-size particles due to an electrostatic 
interaction between the positive charge group on the polymer and the phosphate group on 
the DNA backbone. Polymer and DNA complexes are called polyplexes. Polymers can 
be designed with varying properties by adjusting the molecular weight distribution, 
degree of cross-linking between the monomers, and also by incorporating targeting 
ligands in the polymer for targeted delivery. Some commonly used cationic polymers are 
PEI (polyethylenimine), PLL (Poly(L-lysine)), chitosans, and dendrimers. There are also 
many disadvantages when working with cationic polymers. When comparing transfection 
efficiency, cationic polymers are less efficient than viral vectors in gene delivery. 
Another disadvantage with cationic polymer is the inability to control the molecular 
weight distribution and dispersities during the production process of synthetic polymers 
(14). 
1.4.1 Mechanism of action  
A cationic polymer system must be able to accomplish the following things: (1) 
capable of binding negatively charged DNA and self-assembly into a vesicle, (2) 
internalization into the targeted cell, (3) facilitate endosomal escape, and (4) unloading of 
genetic material. Once the genetic material is released into the cytosol of the cell it must 
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be capable of bypassing the nuclear envelop and localize to the nucleus in post mitotic 
cells for gene expression to occur. This can be achieved by incorporating a nuclear 
localization sequence (NLS) into the plasmid DNA. For dividing cells, incorporating a 
NLS into the plasmid DNA can increase transfection efficiency but is not necessary for 
expression since the nuclear envelop is broken down during mitosis.  
1.4.2.1 DNA binding and the determination of N/P ratio 
 Cationic polymer must be capable of binding specifically to DNA in order to 
condense it and be able to deliver it into the cell. Work done by Sunshine et al has shown 
that the formation of small, positively charged nanoparticles is a prerequisite for efficient 
transfection (13). Since polymer mediated gene deliver is based on the electrostatic 
interactions of the polycation with the negatively charged phosphate groups of DNA, 
DNA condensation is therefore a function of the cation-to-anion ratio. For cationic 
polymers that have amine functional groups, the calculation of the N/P ratio (where N is 
the moles of nitrogen on the polymer and P is the moles of phosphate in the DNA 
plasmid) is vital in determining whether a stable polyplex will form with DNA. For one 
µg of DNA there are 3 nmol of phosphate (17). In a recent study by Varkouhi et al (18), it 
was found that PDMAEMA (poly(2-(dimethylamino)ethylmethacrylate)), QNPHOS 
homopolymer ((quaternized poly[3,5-bis(dimethylaminomethylene)-p-hydroxy 
styrene])), and QNPHOS-PEG block copolymer were able to form complexes with both 
siRNA and DNA over an N/P range of 0.5 to 16 (18). They also found that polyplex 
formed at an N/P ratio ≥ 2 formed nanoparticles that are ≤ 200 nm in size. The decrease 
in polyplex size is due to an increased in polymer amount in the formulations. This leads 
to a formation of a tighter condensed complex.  
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1.4.2.2. Internalization of cationic polymers  
The general pathway for cationic polymers to move from the extracellular space 
into the nucleus is not fully understood. There are two possible routes for the movement 
of extracellular polyplexes into the cytosol: (1) the fusion of cationic polymers with the 
plasma membrane and (2) endocytosis of the cationic polymer. Endocytosis is a general 
term for the internalization of extracellular particles (fluids, solutes, macromolecules, 
etc.) by invagination of the plasma membrane and the formation of the vesicles and 
vacuoles through membrane fission (16). It is generally perceived that carrier-plasma 
membrane fusion is the more favorable approach for internalization since it avoids the 
endosomal compartment and its acidic pH which results in DNA/RNA degradation. 
However studies of electron and fluorescence microscopy have shown that the cationic 
carriers can be detected within intracellular vesicles (11). This can suggest that 
internalization is a result of endocytosis. 
There are multiple endocytic pathways that can be used by cationic polymers to 
enter the cell. Some of the available pathways are clathrin-mediated endocytosis via 
coated pits, phagocytosis, and macropinocytosis. It’s believed that the predominant way 
of entry for cationic gene delivery systems is by a non-specific adsorptive endocytosis 
process followed by the clathrin-coated pit mechanism (11). Cellular uptake of 
polyplexes can occur by either a caveolae mediated or clathrin-coated pits mechanism. 
 
1.4.2.3. Endosomal escape 
 Once inside the cell the cationic polymer has to escape the endosomal 
compartment before it matures to the late endosomal stage. At the late endosomal stage 
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the endosome is merged with a lysosome and the cationic polymer and its content is 
degraded (16). The exact mechanism of endosomal escape is unknown but there are 
several hypothesis that can explain the process. One possible mechanism for endosomal 
escape is the proton sponge effect. The proton sponge phenomenon has been observed in 
certain cationic polymers with a high pH buffering capacity (11,15). During the 
endosomal maturation process in the cytosol, membrane-bound ATPase proton pumps 
actively transfer protons from the cytosol into the endosomes. This leads to the 
acidification of the endosomal compartments and the activation of the hydrolytic 
enzymes to break down materials within the endosome. Polymers with amine groups will 
resist the acidification mechanism by protonation. As a result of the protonation effect by 
the amine group more protons will be pumped in by the ATPase pumps in an attempt to 
reduce the pH level. The proton pumping action leads to a passive diffusion of chloride 
ions through the endosomal membrane, leading to an increase in ion concentration. The 
increased ion concentration within the endosomal compartment causes an influx of water.  
Eventually the osmotic pressure within the endosome leads to its rupture and the release 
of the polymer vesicle. 
1.4.3. Cationic polymers in used 
 There are plenty of cationic polymers currently in use. Some of the more notable 
ones are Poly(ethyleneimine), Poly(L-Lysine), chitosan, and dendrimers. 
1.4.3.1. Poly(ethyleneimine) (PEI) 
 Among the various available synthetic polymers available for gene delivery, PEIs, 
are the most wildly used due to its high nucleic acid condensing capability, ability for 
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endosomal escape and nuclear localization abilities (28). PEI can be synthesized for 
different lengths and can either be branched or linear. They can undergo functionalized 
group substitution or addition and are a very versatile polymer. PEI polymers can 
successfully bind and condense DNA molecules to form a homogenous spherical particle 
due to their high positive charge density. High MW PEIs are very efficient at gene 
delivery but are also very toxic due to their high positive charge density, whereas, low 
MW PEIs are less toxic than high MW PEIsbut are not as efficient for gene delivery 
(7,9,11,14,28). PEIs have a large amount of non-protonated amines with different pKA 
values on their polymer backbone. This leads to PEIs having a large pH buffering 
capacity, which facilitates rapid endosomal escape via the proton sponge effect. Due to 
their non-biodegradability and high amount of positive charge, PEIs are highly toxic in 
vivo.  
1.4.3.2. Poly(L-lysine) (PLL) 
 PLL is a biodegradable polymer. High molecular weight PLL is more suitable for 
gene delivery via systemic injection (11,14). Cationic PLL interacts with anionic DNA 
molecules to form a positively charged complex that can interact with a negatively 
charged cell surface to undergo rapid internalization. PLL has a low level of transfection 
efficiency when compared to PEI because it lacks a way for rapid release from the 
endosomal compartment. PLL is immunogenic and toxic due to its amino acid backbone. 
A degradable PLL analogue, poly(a-[4-amino-butyl]-L-glycolic acid) (PAGA) showed 
significantly higher transfection efficiency than PLL and had no detectable cytotoxicity 
issues.  
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Guo et al (29) has shown that PEGylated cholic acid modified PLL was capable 
of systemic delivery of siRNA to suppress prostate cancer cells in mice. The PLL was 
chemically modified with cholic acid on one side of the polymer backbone and 
subsequently grafted with poly(ethylene glycol) on the other side via a benzoic imine 
(28). This novel PLL structure is capable of forming cationic micelles that contain a 
hydrophobic core where water-insoluble molecules can be encapsulated and a hydrophilic 
surface where nucleic acid can be complexed.  
14.3.3. Chitosan 
 Chitosan is a biodegradable and biocompatible linear aminopolysaccharide that is 
a copolymer made up of 1,4 linked N-acetyl-D-glucosamine and D-glucosamine subunits 
(11, 14, 30). Chitosan is formed by the alkaline deacetylation of chitin, which is a 
polysaccharide found in the exoskeleton of crustaceans. It is a good candidate for a gene 
delivery system because positively charged chitosan can complex and bind DNA 
effectively. It is a possible alternative to PEI due to its lower cytotoxicity. When chitosan 
is complex with pDNA, it forms stable, small nanoparticles ranging from 20-500 nm. 
Chitosan provides protection against DNase degradation that is comparable to PEI, 
however the transfection efficiency is lower than that of PEI. In a study, by Hu et al (31), 
tumor growth was suppressed with amphiphilic stearic acid-g-oligosaccharide (CSOSA) 
that was conjugated with PEI. 
14.3.4. Dendrimers  
 Dendrimers are spherical, highly branched polymers. Dendrimers have a unique, 
hierarchical, three-dimensional structure. This 3D spherical structure offers synthesis 
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control of the molecule in terms of degree and generation of branching. This control can 
produce polymer particles with a very low degree of polydispersity. This low 
polydispersity can lead to reproducible gene delivery and a clinically reliable 
formulation. The most commonly used dendrimers are polyamidoamine (PAMAM) 
because of its high transfection efficiency. Two commercially available dendrimer 
formulations that are currently in use for in vitro gene delivery are Superfect and 
Polyfect.   
1.5. Novel polymer: poly(PEG-dodecanoate) (PEGD) 
 There has been an increase in interest towards the development of synthetic 
polymers for applications in gene therapy. With synthetic polymers we can modify the 
backbone to improve efficiency or to incorporate a targeting ligand for specific cell types 
for targeted gene delivery by a systemic approach. In our lab we have formed a novel 
polymer of (poly(polyethylene glycol-dodecanoate)) (PEGD). PEGD is a polyester of 
PEG and dodecanedioic acid (see Figure 1). Formation of the polymer is through ester 
bonds and degradation occurs by hydrolysis. PEGD is a linear viscous polymer.  PEGD is 
formed by mixing PEG and dedcanedioc acid at a 1:1 molar ratio and heating at 120˚ C 
for 1-3 days. After the 3rd day the polymer is completely cured.  
 
Figure 1. PEGD polycondensation reaction of PEG and DDA monomers.  
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1.5.1. Polyethylene glycol (PEG) 
 Polyethylene glycol (PEG) is a polyether compound with many applications from 
industrial manufacturing to medicine. PEG has very low toxicity, immunogenicity and 
antigenicity (19). PEG is known to be non-biodegradable but it is readily excretable after 
administration into living organisms. PEG can be covalently attached to a therapeutic 
drug or compound as a way to mask it from the immune system.  
1.5.2. Dodecanedioic acid (DDA) 
 Dodecanedioic acid is a white solid with a slight odor. At 20 degree Celsius the 
relative density is 1.172 which is slightly higher than that of water. It has a melting point 
of 128 degree C and a boiling point of 250 degree Celsius. It is biodegradable, 
biocompatible and has a low bioaccumulation potential. It is not known to be mutagenic, 
genotoxic, or carcinogenic. It can be metabolize to provide energy through fatty acid 
oxidation (22). DDA has a long hydrocarbon chain and an increase in DDA polymer 
composition leads to an increase in hydrophobicity.   
1.5.3. Furmaric acid 
 Furmaric acid, also known as fumarate, trans-Butenedioic acid, allomaelic acid, 
and boletic acid, has a molecular formula of C4H4O4. It has a molecular weight of 116.1. 
Furmaric acid is used in oral pharmaceutical formulations and food products and is 
generally regarded as relatively nontoxic. It has an internal alkene group between Carbon 
2 and Carbon 3.  
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1.5.4. Itaconic acid 
 Itaconic acid is also known as butanedioic acid. It has a molecular formula of 
C5H6O4. It has a molecular weight of 130.1. It is non-toxic and is readily biodegradable. 
It has a terminal alkene group at Carbon 2.  
1.5.5. Addition of FA and IA to PEGD backbone 
 PEGD polymers can be further modified to incorporate a double bond in the 
polymer backbone by the addition of either furmaric acid (FA) or itaconic acid (IA) 
during the polycondensation reaction. Varying the ratio of FA/IA to DDA would lead to a 
change in the hydrophobicity. Higher concentration of DDA would lead to a more 
hydrophobic polymer due to the long hydrocarbon chain on DDA.  
 
 
Figure 2. PEGDF and PEGDI polymers. 
1.5.6. Cys-(Arg)n 
 Cys-(Arg)n is a peptide that can be synthesis with the use of 1,1’-
Carbonyldiimidazole (CDI). The Cys-(Arg)n peptide will have a Cysteine head and an 
Arginine tail. Cysteine and Arginine are both semi essential amino acids. The thiol side 
chain on Cysteine can serve as nucleophile in chemical reactions. Every Arginine residue 
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has four nitrogen atom and in a Cys-(Arg)n where n=8, there is a total of 32 total nitrogen 
atoms. This will contribute greatly to the positive charge density of the peptide chain. 
1.6 HEK 293 Cells 
 HEK293 (human embryonic kidney) cells are a cell line that has been extensively 
used as an expression tool for recombinant proteins. Graham et al transformed the human 
embryonic kidney cells after exposing them to sheared fragments of human adenovirus 
type 5 (Ad5) (25). The introduction of foreign plasmid vectors (especially those with a 
cytomegalovirus (CMV) promoter) can effectively hijack the cells protein machinery and 
force the translation of gene products that were artificially incorporated into the plasmid 
vector. Although of epithelial origin, HEK293 cell’s biochemical machinery is capable of 
generating functional protein from a wide spectrum of both mammalian and non-
mammalian nucleic acids (25). HEK293 can also be stably transformed to express protein 
units that are not native to its cellular makeup. They serve as a powerful tool for transient 
gene expression studies. 
1.7 Alamar Blue Cytotoxicity 
 Cell health can be monitored by numerous methods from plasma membrane 
integrity, DNA synthesis, DNA content, enzyme activity, and cellular reducing 
conditions, known indicators of cell viability and cell death (33). Alamar Blue (Thermo 
Scientific) is a cell heath indicator that measures the reducing power of living cells to 
quantitatively measure the proliferation of various human and cell lines. Healthy cells 
maintain a reducing environment within the cytosol of the cell. The active ingredient in 
Alamar Blue is Resazurin, a non-toxic cell permeable compound that is blue in color and 
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virtually non-fluorescent. Resazurin is reduced to resorufin (a red and highly fluorescent 
compound) in healthy cells. By measuring the fluorescent intensity of cells exposed to 
resazurin, we can quantitatively determine their viability.  
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CHAPTER 2: STATEMENTS AND SPECIFIC AIMS 
2.1 Statement of purpose 
From the described characteristic of PEGD it is believed that it may be a good 
candidate for use as a gene delivery vector. Modification of PEGD is needed to make it 
viable for binding DNA. PEGD in its unmodified form has no cationic charge, therefore 
we will need to find a way to incorporate a positive charge to the PEGD polymer 
backbone to allow for polymer/DNA electrostatic interaction. We can do this in a two-
step process. First, we can introduce an alkene group onto the PEGD polymer backbone 
by adding either furmaric acid or itaconic acid and adjusting the ratio of furmaric acid or 
itaconic acid to DDA during PEGD synthesis. Second, we can perform a Michael 
Addition Reaction to bind a cationic ligand to the alkenes located on the 
furmaric/itaconic acid monomers throughout the polymer backbone. Some possible 
ligands that can be used are protamine sulfate and Cys-(Arg)n.   
 The scope of this thesis is to test whether or not the modified PEGD polymer will 
be suitable for gene transfection. If the PEGD polymer is capable of transfection then it 
will be a novel polymer base gene delivery system. It is believed that PEGD modified 
with Cys-(Arg)n will be able to condense DNA effectively and be capable of transporting 
it into the cell for transfection.  
2.2 Specific Aims 
Aim 1, to synthesize PEGD modified with an 80:20 ratio of DDA to either furmaric acid 
or itaconic acid. This modified PEGD will be further modified by binding a cationic 
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ligand (such as protamine sulfate or Cys-(Arg)n) to the double bond of the furmaric acid 
or itaconic acid monomer.  To also characterize the modified PEGD polymer by Raman 
spectroscopy, gel permeation chromatography (GPC), and dynamic light scattering 
(DLS). 
Aim 2, to determine if modified PEGDF/I polymers are capable of binding DNA, 
transfect HEK 293 cells and their effects on cellular viability. 
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CHAPTER 3 METHODLOGY 
 
3.1 Synthesizing polymer 
3.1.1 Preparation of PEGDF and PEGDI polymers  
Polyethylene glycol (PEG, MW 202), fumaric acid (FA, mw 116.07), itaconic 
acid (IA, mw 130.1), dodecanedioc acid (DDA, MW 232.2) were purchased from Sigma 
Aldrich. PEGDF and PEDGI will be prepared by mixing PEG and DDA/furmaric acid or 
itaconic acid at a 1:1 ratio. The ratio of DDA to furmaric acid or itaconic acid are 80:20. 
The mixture will be heated at 120 degrees Celsius. PEG DDA/furmaric acid or itaconic 
acid is polymerizing due to ester bond formation. Polymer samples will be collected at 24 
hrs and 48 hrs to acquire different MW distribution. 
3.1.2. Acquiring of Cys-(Arg)8 and protamine sulfate  
Cys-(Arg)8 (CA, 5 mg white powder) was purchased commercially from 
Biomatik. The sequence ordered was Cys-Arg8. The molecular formula is 
C78H123N35O14S with a MW of 1783.11. Protamine sulfate (PS) was purchased from 
Sigma-Aldrich.  
3.1.3. Modification of PEGDF and PEGDI with Cys-(Arg)8 and Protamine Sulfate 
PEGDF and PEGDI were modified with Cys-(Arg)8 and Protamine sulfate via the 
Michael addition reaction. Michael addition reaction is a nucleophile addition to an α,β-
unsaturated carbonyl compound. The thiol Michael addition reaction rates increase with 
pH (23). For protamine sulfate modification, a 2% solution of PS was made with DI 
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water (Lab source). 20 µg of 48 hr polymer sample of PEGDF and PEGDI was mixed 
with 100 µl of the 2% PS solution. The samples were incubated at 37 degrees C for 3 hrs. 
For modification with Cys-(Arg)8, 1 mg vial of CA was dissolved in 1 ml of PBS, pH 8, 
for a 1mg/ml solution. 20 µg of day 2 sample of PEGDF and PEGDI was mixed with 200 
µl of 1mg/ml solution of CA and incubated at 37˚ C for 3 hrs.  
3.2. Characterization of the Polymer 
3.2.1 Raman Spectroscopy 
Raman Spectroscopy is a spectroscopic technique that is used to observe 
vibrational, rotational, and other low-frequency modes in a system. It is based upon the 
inelastic scattering of radiation (usually in the visible or near-infrared region). It relies on 
the inelastic or Raman scattering of monochromatic light (a laser). The laser interacts 
with the molecular vibrations, phonons, or other excitations in the system. This 
interaction results in the energy of the laser photons being shifted up or down and the 
shift in energy gives information about the vibration modes in the system. We will be 
using Raman Spectroscopy to determine if the Michael addition of Cys-(Arg)8 and 
Protamine Sulfate  to the polymer was successfully. The absence of a strong peak at 
around ~1600 cm-1 would signify that bonding has occurred between the amine and the 
thiol to the alkene of the polymer backbone. 
Raman spectra was taken with Raman Micro 400 Series Raman Spectroscopy 
(Perkin Elmer) using a 50X objective lens and with a 2 to 4 second exposure time. These 
spectrum data were used to evaluate the polymerization process and the chemical 
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structure of PEGDF and PEGDI pre and post modification. Samples were pipette onto the 
shiny side of an aluminum foil and microscope slides.  
3.2.2. Gel Permeation Chromatography  
Gel permeation chromatography (GPC) is a size exclusion chromatography that 
separates analytes on the basis of size. GPC was carried out on the Prominence GPC 
System. 2 mg of polymer sample were dissolved in tetrahydrofuran (THF). 
3.2.3. Dynamic Light Scattering (DLS)  
 Modified PEGDF and PEGDI polymers size were measured by dynamic light 
scattering (DLS) using a Malvern Zetasizer (Malvern Instruments, Worcestershire, 
United Kingdom). Size measurements were taken at 25˚C using a 1:30 (vol/vol) dilution 
of the modified polymer suspension and GFP plasmid in deionized (DI) water. The 
polydispersity index (PDI) was used as a measure of particle size distribution.  
3.3. Determination of modified PEGD transfection capabilities 
3.3.1. Determination of modified PEGDF and PEGDI binding capabilities  
Cationic polymers must be capable of binding specifically to DNA in order to 
condense it and be able to deliver it into the cell. The purpose of this experiment is to be 
able to quickly test whether the cationic formulation will function as a viable gene 
delivery vehicle. The binding assay was conducted and checked via gel electrophoresis. 
Modified PEGDF and PEGDI polymers will be allowed to complex with DNA for 30 
minutes at RT. They will then be loaded on a 1% agarose gel and allowed to run at 100 V 
for 45 minutes in TAE buffer. The agarose gel will then be stained with Sybr Green (a 
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nucleic acid dye) for 40 minutes. The agarose gel will then fluoresce by blue light and a 
Nikon 35mm DLS is used to capture a picture of the gel at 3200 ISO (light sensitivity of 
the camera, higher ISO leads to an increase in light sensitivity)  with 4 sec exposure.  
3.3.2 Culturing of HEK 293 Cells 
Human Embryonic Kidney 293 cells (HEK 293) were generously provided by 
Tatiana Slepak of the LemBix Lab (Miami Project Cure for Paralysis, University of 
Miami). HEK 293 cells were maintained with Dulbecco’s Modified Eagle Medium: 
Nutrient Mixture F-12 (DMEM/F12) with 10% fetal bovine serum (FBS) and incubated 
at 37˚C with 5% CO2. Media was changed every 3 days and cells were passed when 
confluency was ~90% with trypsin + 0.05% EDTA   
3.3.3 Cell viability via Alamar Blue Assay 
Cell viability will be determined by an Alamar Blue Assay (ThermoFisher 
Scientific) which measures cell health by their ability to reduce resazurin (the active 
component in Alamar Blue) into resorufin (a compound that is red in color and highly 
fluorescent) (28). 15,000 HEK293 cells were plated in a 12 well plate. A 10% Alamar 
Blue solution was made with DMEN/F12 culture medium. Cells were incubated with 
Alamar Blue solution for 4 hrs at 37˚C. Three 100 µl samples per group (n=3) were 
gathered at day 0 (prior to incubation with modified polymers), day 1, day 2, and day 4 
for each group. Samples were measured for fluorescence intensity to determine cell 
viability.   
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3.3.4. Transfection study in HEK 293 Cells 
PEGDF and PEGDI modified with PS and CA are tested to determine if 
transfection will occur in HEK 293 Cells. HEK 293 cells will be transfected with 
pTurboGFP. If transfection is successful then expression of GFP will be seen when the 
cells are exposed to light in the blue to ultraviolet range. Transfected cells will exhibit a 
bright green fluorescence.  
HEK 293 cells will be plated in 35 mm culture dishes. The total amount of cells 
per plate will be ~50,000 cells. Modified PPEGDF and PPEGDI will be allowed to 
complex with pGFP for 30 minutes prior to transfection. Polymer/DNA solution will be 
added drop wise to the HEK293 cells. After 4 hours the media will be change and cells 
will be visualize at 24 hrs, 48 hrs, and 72 hrs. Pictures will be taken of the transfected 
cells.    
3.3.5 Transfection efficiency  
Cell Profiler is a free, open-source software designed to quantitatively measure 
phenotypes from images. It is capable of quantifying the transfection expression rate 
amongst the different modified polymers. From this information transfection efficiency 
can be determine and compared between the different polymers samples used. Cell 
profile requires establishing proper pipelines for data analysis and proper imaging 
modules using the right algorithms to help filter out noise and identify the proper object 
of interest (such as cell count and transfected cells).  
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Images were taken 24 hr post transfection of HEK 293 cells. A total of 20 images 
were taken per group (10 bright field and 10 fluorescence). Images were loaded into Cell 
Profiler and a pipeline of image modules were used to filter the images and identify the 
objects of interest within the images (such as transfected and non-transfected cells). 
3.4 Statistical Analysis 
 Statistical significance was identified by one-way ANOVA (SPSS, Chicago, 
Illinois) for the difference among treatment and control groups. A p-value <0.05 was 
considered to be statistically significant.  
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CHAPTER 4 RESULTS 
 
4.1 Results accomplished for Specific Aim 1 
4.1.1 Raman Spectra of PEGDI/F Polymers 
The Raman spectra of both PEGDF and PEGDI shows peaks at 1735 cm-1 
indicating the appearance of typical ester bonds, which is an indicator of polymer 
formation by esterification or the formation of ester bonds (Figure 3). Also peaks at 1655 
cm-1 indicates the presence of a carbon-carbon double bond, a necessary component for 
polymer modification by the Michael addition reaction. 
 
Figure 3. Raman spectrum of PEGDF and PEGDI Polymers shows peaks at 1735 cm-
1(blue circle) and 1655 cm-1 (red circle) indicating the presence of ester bonds and 
carbon-carbon double bonds, respectively. 
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4.1.2 Dynamic Light Scattering of modified PEGDF/I Polymers 
 The mean size for dynamic light scattering (DLS) data gives us modified cationic 
polymers (CPs) and DNA polyplexes sizes that ranges from 130 to 170 nm (see table 1 
and figure 4). Commercially bought JetPEI was able to condense DNA and form 
polyplexes with diameters of around 80 nm. The polydispersity (PDI) values measured 
for modified CPs/DNA polyplexes were around 0.8 which signifies the polyplex solution 
contains large aggregates and or sedimentation. From the DLS readings there were 
instances of two peaks showing different diameter values: a large value (>1500 nm) and a 
smaller value (~160 nm). The larger peaks had a smaller intensity (<10%).  There was a 
statistically significant difference in polyplex size between groups as determined by one-
way ANOVA (F(4,14)=33.957, p<0.0001). A Tukey post-hoc test showed that there is a 
difference in polyplex size between PEGDF+PS (p<0.00001), PEGDI+PS (p<0.00001), 
PEGDF+CA (p<0.00001), and PEGDI+CA (p<0.0007) when compared with JetPEI 
polyplexes. 
Formulation Size (nm (SD) Polydispersity (PDI) (SD) 
PEGDF+PS/DNA PolyPlex 171.7± 15 0.78± 0.05 
PEGDI+PS/DNA Polyplex 161.3±13.7 0.79± 0.001 
PEGDF+CA/DNA Polyplex 161.3 ±  5.5 0.8 ± 0.05 
PEGDI+CA/DNA Polyplex 136 ± 12 0.785 ± 0.002 
JetPEI/DNA Polyplex 78±7 0.214 ± 0.01 
 
Table 1. Mean size and PDI values for modified PEGDF and PEGDI polymers (n=3). 
There was a statistical difference between modified PEGDF/I polymers and JetPEI 
polyplex sizes (p<0.0001).    
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Figure 4. Mean size of modified PEGDF and PEGDI polymers (n=3). Error bars are SD. 
There was a statistical difference between modified PEGDF/I polymers and JetPEI 
polyplex sizes (p<0.0001).    
 
4.1.3 GPC of PEGDF/PEGDI polymers 
The MWs measured by GPC column of PEGDF and PEGDI are listed in Table 1. The 
increase in MW shows an elongation of polymers by esterification—the longer the 
reaction was allowed to run. Polymer samples that were taken after 24 hrs have a MW of 
1552 Da and 1334 Da for PEGDF and PEGDI, respectively. After 48 hrs of reaction, the 
polymers MW increased by 1000 Das.  
  24 48 
Formulation MW MN MW MN 
PEGDF 1552  1016  2995  1576  
PEGDI 1334  924  2561  1483  
 
 Table 2. GPC measurements of PEGDF and PEGDI polymers. The increase in polymer 
MW shows polymer elongation occurring by esterification.  
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Figure 5. GPC measurements of PEGDF and PEGDI polymers. A change in MW from 24 
hrs to 48 hrs showed polymer elongation by esterification.  
 
4.2 Results accomplished for Specific Aim 2 
4.2.1 DNA Binding Assay 
PEGDF and PEGDI Polymers modified with protamine sulfate and Cys-Arginine 
were tested for their binding capabilities through the gel binding assay. Commercially 
bought JetPEI was used as a positive control and DNA plasmids alone were used as a 
negative control. The assay showed that all forms of modified PEGDI and PEGDF were 
capable of binding and condensing DNA (Figure 6) and prevented the migration of GFP 
plasmid through the agarose gel. The surface charge of PEGDF and PEGDI polymers 
modified with PS was strong enough to bind bromophenol blue (a negatively charged 
leading dye) whereas polymers modified with Cys-Arg and JetPEI were unable to bind 
bromophenol blue.      
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Figure 6. Gel binding assay. PEGDF and PEGDI modified with protamine sulfate (PS) 
and Cys-Arginine (C) were capable of binding and retarding the migration of GFP 
plasmid through the agarose gel. pGFP was complexed with the different variations of 
modified polymers, JetPEI, and nothing(the control). Gel was stained with SybrGreen (a 
nucleic dye) and fluoresce under a blue LED light. As seen in the figure all of the groups 
were capable of binding pGFP and prevent its migration through the agarose gel 
whereas the control (GFP alone) showed the pGFP plasmid migrating through the 
agarose gel. 
 
Figure 7. Gel binding assay. Unstained image of agarose gel under normal light. Here 
you can see that PEGDF/I modified with protamine sulfate (PS) has a high enough 
surface charge that it was capable of binding bromophenol blue, whereas PEGDF/I 
polymers modified with Cys-Arg and JetPEI were unable to bind bromophenol blue.  
4.2.2 In vitro cytotoxicity analysis of modified PEGDF/I polymers by Alamar blue assay 
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PEGDF-PS, PEGDI-PS, PEGDF-CA, PEGDI-CA, and JetPEI were tested for 
their cytotoxicity with the alamar blue assay. Samples were loaded onto a 96 well plate 
and the fluorescence intensity values were measured from Day 0 to Day 4. There was a 
statistically significant difference in mean intensity value between groups as determined 
by one-way ANOVA (F(5,48) =24.637, p<0.001). A Tukey post-hoc test showed that 
there is a difference in mean intensity values between PEGDF-PS (p<0.0001), PEGDI-PS 
(p<0.0001), and JetPEI (p<0.0001) when compared with the control group, whereas the 
difference in mean fluorescence between control, PEGDF-CA (p>0.05), and PEGDI-CA 
(p>0.05) were not significant. This result shows that polymers modified by PS exhibit 
cytotoxicity whereas polymers modified with CA are not cytotoxic. 
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Figure 8. Alamar Blue Assay of modified polymers. Values are given as mean ± standard 
deviation. Statistical testing shows that PEGDF-PS, PEGDI-PS, and PEI exhibit 
cytotoxicity when compared to the control, whereas PEGDF-CA and PEGDI-CA did not 
exhibit cytotoxicity when compared to the control (n=9). 
  
4.2.3. Transfection of HEK 293 Cells 
 PEGDF-PS, PEGDI-PS, PEGDF-CA, and PEGDI-CA were capable of 
transfecting HEK293 cells with pTurboGFP with varying success (Figure 8). Visually, 
we can see a lower cell density in PEI, PEGDF-PS, and PEGDI-PS groups when 
compared to the control, whereas cell density in PEGDF-CA and PEGDI-CA groups 
were similar to control group.  
 
Figure 9. Transfection of HEK293 cells with modified PEGDF and PEGDI Polymers. A. 
Phase contrast of 24 post transfection. B. Same field fluorescence microscopy of HEK 
293 expressing pTurboGFP (n=3).  
 
4.2.4 Cell Profiler image analysis of transfected cells 
Cell profiler showed that it was capable of identifying cells based upon the 
difference in intensity between the foreground (object of interest) and the background 
(see Figure 9). With the right threshold, the program is able to objectively identify 
A B 
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important objects and provide a count of the objects of interest. The images captured are 
a representation of random fields of the culture plate of transfected cells. Cell profiler 
was used to do a count of total cells in the bright field microscopy and a count of GFP 
positive cells in fluorescence microscopy images (Figure 9).   
 
 
Figure 10. Cell Profiler image analysis of bright-field microscopy images. Threshold 
values were set to identify HEK293 cells in bright-field images.  
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Figure 11. Cell Profiler image analysis of fluorescence microscope images of 24 hr post 
transfection.  
 
4.2.5 Transfection efficiency in HEK293 cells 
Transfection efficiency is determine (see Table 3 and Figure 10) by the fraction of 
transfected cells (GFP positive objects) as a percentage of the total cell count (positive 
object identification in bright field microscopy). Image analysis using Cell Profiler 
showed that PEGDF-PS and PEGDI-PS had very low transfection efficiency of around 
18% and 15%, respectively. PEGDF-CA and PEGDI-CA showed slightly better 
transfection efficiency of 27.8% and 30.7%. Commercially bought JetPEI had a 
transfection efficiency of 45%. There was a statistically significant difference in the 
transfection efficiency between groups as determined by one-way ANOVA (F(5,12) 
=124.688, p<0.0001). Tukey post hoc analysis showed that all of the modified variant 
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groups were statistically (p<0.0001) less efficient than commercially available JetPEI.   
Figure 11 provides a graphical representation of non-transfected cells to transfected cells.  
HEK293 Cells Transfection 
Group Total Cells Transfected Cells Efficiency 
Control 2431 ± 258 N/A N/A 
JetPEI 1704 ± 434 773 ± 166 45.8 ± 3.8 
PEGDF+CA 2353 ± 446 650  ± 101 27.8  ± 2.2 
PEGDI+CA 2427 ± 395 744 ± 127 30.7 ± 2.3 
PEGDF+PS 2200  ± 475 395  ±  109 17.7  ±  1.6 
PEGDI+PS 2318  ± 401 351  ±  72 15.2  ±  2.7 
 
Table 3. Efficiency of transfection of HEK 293 cells. Values are given as mean ± standard 
deviation and were tabulated from Cell Profiler image analysis of 24 hr post transfection 
images of HEK 293 transfection experiments (n=3).  
 
Figure 12. Transfection in HEK293 cells with PEGDFI+CA, PEGDI+CA, PEGDF+PS, 
PEGDI+PS, and JetPEI. These were tabulated cell count values from Cell Profiler image 
analysis. Values are given as mean ± standard deviation (n=3). 
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CHAPTER 5 DISCUSSION AND CONCLUSSIONS  
 
5.1 Characterization of PEGDF and PEGDI polymers 
The molecular weight (MW) of day 2 PEGDF and PEGDI polymers were 2995 
and 2550 Da, respectively. This is consistent with the literature that polycondensation of 
difunctional monomers yield low molecular weight polymers (29). A change in MW 
from day 1 to day 2 in GPC data showed polymer elongation by esterification of 
monomers. Day 2 samples were selected for further consideration in modification due to 
the absence of monomers in the GPC data. 
Figure 2 shows the theoretical chemical structure of PEGDF and PEGDI. Key 
characteristics of the polymer includes ester bonds, double bonds, and a long 
hydrocarbon chain. The region of Raman spectra above 1000 cm-1 is known as the 
characterization region—where discernible functional groups can be identified. The 
Raman spectra of the PEGDF and PEGDI polymers shows characteristic peaks at 1735 
cm-1 which signals the presence of ester bonds within the polymer backbone (31). This 
should be expected due polymer formation is by esterification or the formation of ester 
bonds. Raman spectra data also shows the presence of a peak at 1635 cm-1, signifying the 
presence of double bonds within the polymer backbone—necessary for further 
modification of the PEGDF and PEGDI polymers. The spectra data also shows peaks at 
725 cm-1, which is seen only in long chain alkanes (31).  
DLS results shows modified polymer and DNA polyplexes to be between the 
ranges of 130-170 nm which is an acceptable range for endosomal uptake for in vitro 
studies (18). There are varying reports of the perfect range of DNA polyplexes size for 
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cellular uptake. Wagner et al observed that smaller polyplex size (<100 nm) leads to 
higher in vitro gene transfection of cell mediated uptake is by receptor mediated 
endocytosis but reports have also shown that polyplexes up to 500 nm are capable of 
cellular transfection (18). The zeta potential of a cationic polymer (CP) determines the 
surface charges of the polyplexes. CPs with surface potentials between the ranges of 20 
mV to 40 mV are sufficient in binding DNA and allowing for cellular transfection. 
Unfortunately, zeta potential was not measured for the modified PEDGF and PEDGI 
polymers but it is reasonable to assume that it is within that range since other studies have 
shown that the polymers are capable of binding DNA.  
The PDI values were higher than 0.3 which can indicate a non-homogenous 
formulation of polyplexes (42). Some of the DLS results showed readings of two possible 
diameters, >1500 nm and <170 nm. The larger diameter readings had a smaller intensity 
reading indicating a smaller concentration of particles. These large particles could be a 
result of sedimentation and or aggregation of free floating CPs.  
5.2 DNA binding by modified polymers 
Binding DNA is a basic requirement for cationic polymers to allow for 
transfection into cells. The gel binding assay was an important test that allowed for rapid 
identification of successful PEGDF and PEGDI nucleophilic addition by CA and PS, 
since successfully reacted polymers are capable of binding DNA and retarding its 
migration through the agarose gel. Looking at Figure 6a, we can see that all four 
modified polymers, PEGDF-PS, PEGDI-PS, PEGDI-CA, and PEGDF-CA were capable 
of retarding the migration of DNA through the agarose gel. Figure 6b shows that the 
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PEGDF-PS and PEGDI-PS were also capable of preventing bromophenol blue (a 
negatively charged dye) from migrating through the agarose gel. This is probably due to 
the fact that protamine sulfate has a higher ratio of N to P then compared to the Cys-Arg8 
peptide, so the PEGDF-PS and PEGDI-PS polymers carry a higher surface charge.  
5.3 In vitro cytotoxicity analysis of modified PEGDF/I polymers 
The alamar blue assay is a good indicator of cell viability by determining cells 
capabilities of reducing resazurin to resorufin—cells that are not healthy will be less 
capable of this reducing capability. JetPEI is a commercially available reagent that is 
known to exhibit high toxicity and decreased cell viability (40), was used as a negative 
control. Students t-test showed that the difference in mean fluorescence value on day 4 
samples between PEGDF-PS, PEGDI-PS and JetPEI when compared to the control was 
statistically significant. The difference in mean fluorescence values of PEGDF-CA and 
PEGDI-CA when compared to the control group day 4 showed no statistically 
significance, thus PEGDF-CA and PEGDI-CA do not exhibit cytotoxic effects.  
PEGDF and PEGDI polymers by themselves do not exhibit cytotoxicity since 
they can be readily broken down by hydrolysis of the ester bonds into their monomer 
components of PEG and DDA, both which can be metabolized by cells for energy.  The 
toxic effects of polymers that have PS attachment can be attributed to its high surface 
charge. Increases in cationic surface charges for most NPs correlates to a greater 
cytotoxicity in non-phagocytic cells (41). 
5.4 Cell Profiler image analysis 
39 
 
Cell Profiler demonstrated that it is capable of doing a cell count both in bright-
field and fluorescence images. Image analysis through Cell Profiler requires optimal 
threshold values to filter out noise and get a clear count of cells in bright field and 
fluorescence microscopy images. From the cell count, we were able to get a 
representation of the efficiency of transfection in HEK 293 cells. However, the imaging 
algorithms have a capacity to undercount or over-count based upon the threshold 
established (Figure 8). Nevertheless, this over-counting and under-counting error can be 
negated since the same thresholds will be applied to all the image sets.  
5.5 Transfection of HEK 293 cells 
 Transfection in HEK 293 cells with modified PEGDF and PEGDI polymers were 
successful but showed varied efficiency. PEGDF-PS and PEGDI-PS had very low 
transfection efficiency of around 18% and 15%, respectively. PEGDF-CA and PEGDI-
CA showed slightly better transfection efficiency of 27.8% and 30.7%. JetPEI, a 
commercially available reagent was shown to have an efficiency of around 45%, which is 
close to its expected efficiency. The varied efficiency between polymers modified by CA 
and PS ligands can possibly be explained by the characteristics of the cationic polymers. 
PEGDF and PEGDI polymers modified with PS exhibit a higher charge potential as can 
be deduce from its ability to bind bromophenol blue in the gel binding assay experiment. 
This higher charge density leads to a stronger affinity for negatively charged DNA. Also, 
it is possible that once inside the cytoplasm of cells the protamine sulfate ligands can 
prevent degradation of polymeric vesicles for release of pTurboGFP plasmids.  
5.6 Conclusion 
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 PEGDF and PEGDI polymers modified by the Michael addition of protamine 
sulfate (PS) and CysArg8 (CA) showed that they are capable of binding and condensing 
DNA into compact polyplexes. Polymers modified with PS are found to be cytotoxic, 
whereas polymers modified with CA are not. Transfection in HEK 293 with modified 
polymers were successful but showed varying efficiency. PEGDF+CA and PEGDI+CA 
showed transfection efficiency that ranges between 26-32%. This is still lower in 
efficiency than commercially available JetPEI, but the tradeoff in non-cytotoxic nature of 
PEGDF+CA and PEGDI+CA showed that these polymers could be promising candidates 
for further consideration.  
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